NASDAQ:VBLT

Vascular Biogenics (VBLT) Stock Forecast, Price & News

$0.24

0.00 (-0.12%)

(As of 05:37 PM ET)

Compare

Today's Range: $0.24
▼
$0.26
50-Day Range: $0.21
▼
$0.31
52-Week Range: $0.10
▼
$0.32

Volume: 447,059 shs
Average Volume: 2.22 million shs
Market Capitalization: $18.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Vascular Biogenics (NASDAQ:VBLT) Stock

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

VBLT Price History

30 days | 90 days | 365 days | Advanced Chart

VBLT Stock News Headlines

September 26, 2023 | americanbankingnews.com

Vascular Biogenics (NASDAQ:VBLT) Now Covered by Analysts at StockNews.com

September 9, 2023 | finance.yahoo.com

Vascular Biogenics Rises on Presentation Hype

October 2, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 6, 2023 | finance.yahoo.com

VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC

August 28, 2023 | businesswire.com

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT

August 28, 2023 | businesswire.com

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT

August 14, 2023 | finance.yahoo.com

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

July 23, 2023 | fool.com

Vascular Biogenics (NASDAQ: VBLT)

October 2, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 15, 2023 | finance.yahoo.com

VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

April 4, 2023 | benzinga.com

Vascular Biogenics Stock (NASDAQ:VBLT), Dividends

March 17, 2023 | finance.yahoo.com

Vascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)

March 14, 2023 | finance.yahoo.com

VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

March 9, 2023 | finance.yahoo.com

VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash

February 27, 2023 | prnewswire.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vascular Biogenics Ltd. - VBLT

February 23, 2023 | technews.tmcnet.com

VBLT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Vascular Biogenics Ltd. Is Fair to Shareholders

February 23, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vascular Biogenics Ltd. Merger

February 23, 2023 | marketwatch.com

Vascular Biogenics Shares Jump Premarket on Reverse Merger Plans >VBLT

February 23, 2023 | msn.com

Vascular Biogenics rises 85% on all-stock merger deal with Notable Labs

February 23, 2023 | investorplace.com

Why Is Vascular Biogenics (VBLT) Stock Up 52%?

February 16, 2023 | finance.yahoo.com

VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash

November 10, 2022 | finance.yahoo.com

OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates

September 2, 2022 | finance.yahoo.com

Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07

September 1, 2022 | finance.yahoo.com

VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

September 1, 2022 | finance.yahoo.com

Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product

August 2, 2022 | marketwatch.com

Vascular Biogenics Cutting About 35% of Staff >VBLT

August 2, 2022 | finance.yahoo.com

VBL Therapeutics Announces Workforce Reduction

See More Headlines

Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Company Calendar

Last Earnings: 8/14/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VBLT
Previous Symbol: NASDAQ:VBLX
CUSIP: N/A
CIK: 1603207
Web: www.vblrx.com
Phone: (728) 993-5000
Fax: 972-8993-5001
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,300,000.00
Net Margins: N/A
Pretax Margin: -3,317.05%
Return on Equity: -73.45%
Return on Assets: -54.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.63
Quick Ratio: 4.63

Sales & Book Value

Annual Sales: $481,000.00
Price / Sales: 39.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.32 per share
Price / Book: 0.76

Miscellaneous

Outstanding Shares: 77,640,000
Free Float: 72,881,000
Market Cap: $18.95 million
Optionable: Optionable
Beta: 0.82

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Prof. Dror Harats M.D. (Age 66)
CEO & Director
Comp: $444.33k

Mr. Samuel Backenroth (Age 39)
Chief Financial Officer
Comp: $410k

Dr. Eyal Breitbart Ph.D. (Age 56)
Sr. VP of Research & Operations

Advocate Ayelet Horn (Age 52)
Gen. Counsel

Dr. Erez Feige M.B.A. (Age 49)
Ph.D., Sr. VP of Bus. Operations

Key Competitors

View All Competitors

Institutional Ownership

Simplex Trading LLC
Sold 100 shares on 8/4/2023
Ownership: 0.000%

View All Institutional Transactions

VBLT Stock - Frequently Asked Questions

How have VBLT shares performed in 2023?: Vascular Biogenics' stock was trading at $0.12 at the start of the year. Since then, VBLT stock has increased by 103.4% and is now trading at $0.2441.
View the best growth stocks for 2023 here.
When is Vascular Biogenics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our VBLT earnings forecast.
How were Vascular Biogenics' earnings last quarter?: Vascular Biogenics Ltd. (NASDAQ:VBLT) released its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter.
What other stocks do shareholders of Vascular Biogenics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?: Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."
How do I buy shares of Vascular Biogenics?: Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vascular Biogenics' stock price today?: One share of VBLT stock can currently be purchased for approximately $0.24.
How much money does Vascular Biogenics make?: Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $18.95 million and generates $481,000.00 in revenue each year. The biopharmaceutical company earns $-32,300,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.
How can I contact Vascular Biogenics?: Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.

This page (NASDAQ:VBLT) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial